Korean J Med.  2007 May;72(5):459-469.

Non-invasive assessment of liver fibrosis by measuring the liver stiffness and biochemical markers in chronic hepatitis B patients

Affiliations
  • 1Department of Internal Medicine, Yonsei University College of Medicine, Liver Cirrhosis Clinical Research Center, Seoul, Korea. gihankhys@yumc.yonsei.ac.kr
  • 2Department of Pathology, Yonsei University College of Medicine, Liver Cirrhosis Clinical Research Center, Seoul, Korea.
  • 3Department of Biostatics, Yonsei University College of Medicine, Liver Cirrhosis Clinical Research Center, Seoul, Korea.
  • 4Institute of Gastroenterology, Yonsei University College of Medicine, Liver Cirrhosis Clinical Research Center, Seoul, Korea.

Abstract

BACKGROUND: Transient elastography (FibroScan(R)) is a rapid and non-invasive method to measure liver stiffness and this allow the assessment of liver fibrosis. The aim of this study was to assess the diagnostic accuracy of measuring the liver stiffness in addition to measuring the other biochemical markers such as the aspartate transaminase to platelet ratio index [APRI] and the AST/ALT ratio.
METHODS
We enrolled 228 HBsAg positive patients whose liver stiffness was measured by FibroScan(R) between March 2005 and September 2005. Liver biopsy examinations were performed in 34 patients. The fibrosis (F) was staged on a 0-4 scale according to the Ludwig classification.
RESULTS
According to the clinical diagnosis, the median values of liver stiffness were 7.0+/-2.7 kPa for inactive carriers (n=29), 8.3+/-5.3 kPa for chronic hepatitis patients (n=106), 15.9+/-8.3 kPa for compensated cirrhosis patients (n=63), 31.8+/-20.3 kPa for decompensated cirrhosis patients (n=26), and 45.1+/-34.5 kPa for HCC patients (n=4). The degree of liver stiffness was significantly different between the different disease groups (p<0.001). Liver stiffness was well correlated with the fibrosis stages (r=0.726; p<0.001). The AUROC of FibroScan(R), the APRI and the AST/ALT ratio values were of the same order; 0.72, 0.61 and 0.58, respectively, for F> or =2; 0.92, 0.73, and 0.56, respectively, for F> or =3; and 0.97, 0.79, and 0.55, respectively, for F=4. FibroScan(R) offered the best diagnostic performance both for significant fibrosis (F> or =2) and severe fibrosis-cirrhosis (F3-F4).
CONCLUSIONS
FibroScan(R) is a reliable, rapid non-invasive method to diagnose the severity of chronic liver disease and to predict fibrosis in patients with chronic hepatitis B, in addition to using the APRI and AST/ALT ratio.

Keyword

Hepatitis B; Liver fibrosis; Non-invasive; Diagnosis; Liver stiffness

MeSH Terms

Aspartate Aminotransferases
Biomarkers*
Biopsy
Blood Platelets
Classification
Diagnosis
Elasticity Imaging Techniques
Fibrosis
Hepatitis B
Hepatitis B Surface Antigens
Hepatitis B, Chronic*
Hepatitis, Chronic*
Humans
Liver Cirrhosis*
Liver Diseases
Liver*
Aspartate Aminotransferases
Hepatitis B Surface Antigens
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr